Compare Gilead Sciences, Inc. (GILD) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Gilead Sciences, Inc. trades at $151 (market cap $182.40B), while iShares 1 3 Year Treasury Bond ETF trades at $81.18 (market cap $26.68B). The key difference: Gilead Sciences, Inc. is far larger — about 6.8× iShares 1 3 Year Treasury Bond ETF's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while iShares 1 3 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| GILD | SHY | |
|---|---|---|
Market Cap | $182.40B | $26.68B |
Volume | 4,469,821 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $155.80 | $83.18 |
52-Week Low | $116.74 | $81.05 |
Typical Hold Time | 111 Days | 63 Days |
Enterprise Value | $205.46B | — |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
SHY trades at $81.175, up 0.02% on the day, amid a bearish technical signal driven by moving averages. The stock shows neutral oscillators but faces selling pressure from the ADX indicator. Recent corporate actions include dividends scheduled for late 2026, with payouts of $0.24-$0.25 per share. The broader bond market context, with rising yields, influences sentiment around short-term bond ETFs like SHY.
The outlook for SHY is cautious due to technical bearishness and macroeconomic headwinds from rising interest rates. Opportunities exist for income-focused investors via dividends, but risks include prolonged bond market volatility and Fed policy uncertainty. Investor sentiment remains mixed, balancing yield appeal against duration risk in a higher-rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
